0001209191-22-017398.txt : 20220308
0001209191-22-017398.hdr.sgml : 20220308
20220308210104
ACCESSION NUMBER: 0001209191-22-017398
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220304
FILED AS OF DATE: 20220308
DATE AS OF CHANGE: 20220308
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: BENZENO SHARON
CENTRAL INDEX KEY: 0001780854
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38957
FILM NUMBER: 22723662
MAIL ADDRESS:
STREET 1: C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION
STREET 2: 1551 EASTLAKE AVE E STE 200
CITY: SEATTLE
STATE: WA
ZIP: 98102
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Adaptive Biotechnologies Corp
CENTRAL INDEX KEY: 0001478320
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 270907024
STATE OF INCORPORATION: WA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1165 EASTLAKE AVE E
CITY: SEATTLE
STATE: WA
ZIP: 98109
BUSINESS PHONE: 206-659-0067
MAIL ADDRESS:
STREET 1: 1165 EASTLAKE AVE E
CITY: SEATTLE
STATE: WA
ZIP: 98109
FORMER COMPANY:
FORMER CONFORMED NAME: Adaptive TCR Corp
DATE OF NAME CHANGE: 20091209
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-03-04
0
0001478320
Adaptive Biotechnologies Corp
ADPT
0001780854
BENZENO SHARON
1165 EASTLAKE AVENUE E
SEATTLE
WA
98109
0
1
0
0
Chief Business Development Off
Common Stock
2022-03-04
4
A
0
82372
0.00
A
105266
D
Common Stock
2022-03-07
4
S
0
2670
12.01
D
102596
D
Stock Option (Right to Buy)
12.14
2022-03-04
4
A
0
205931
0.00
A
2032-03-04
Common Stock
205931
205931
D
This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
The options vest with respect to 1/4 of such shares on March 4, 2023, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
/s/ Sharon Benzeno by Eric Billings, attorney-in-fact
2022-03-08